US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Neuroscience and Healthcare ETF

32.55

-0.3131-0.95%

Post-market: 32.55-0.0070-0.02%17:07 EDT

Volume:432

Turnover:14.10K

Market Cap:6.51M

PE:- -

High:32.56

Open:32.56

Low:32.55

Close:32.87

52wk High:43.01

52wk Low:27.16

Shares:200.00K

Float Shares:200.00K

Volume Ratio:0.31

T/O Rate:0.22%

Dividend:0.32

Dividend Rate:0.98%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $83,464.02

Xenon Grants 17,850 Inducement Stock Options, 10,500 RSUs to New Hires Under NASDAQ Rule

Praxis Precision Medicines Grants 3,478 Inducement RSUs to 14 New Employees Under 2024 Plan

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines, Inc. : Jonestrading Raises Target Price to $534 from $441

THOMSON REUTERS

Alkermes (ALKS), What Is Behind The Fresh Attention?

Simply Wall St.

Dianthus Therapeutics Grants New Hires Stock Options for 106,000 Shares at $88.32 Each

Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Analyst Justin Walsh Reiterates Buy on Praxis as Upgraded Relutrigine Forecast Triples Long-Term Revenue Potential

Xenon's AZK Approval Path Unlikely to Be Hurt by Safety Issues, RBC Says

MT Newswires Live

Xenon Pharma CEO Ian Mortimer Acquires $1,121,400 in Common Shares

How to Build an OPC in Hebei

Dianthus Therapeutics to Present Phase 3 Captivate Interim Analysis of Claseprubart in CIDP at 2026 AANEM Meeting

Defence Therapeutics Appoints Ex-Xenon CFO Sherry Aulin to Board, Audit Committee

Sichuan to Leverage Technology So More People with Disabilities Can See, Hear, and Stand Up | Focus on "15th Five-Year Plan" Disability Support in Sichuan (Part 3)

Xenon Pharmaceuticals Inc. : Jefferies Cuts Target Price to $90 from $100

THOMSON REUTERS

China Securities Co., Ltd.: Brain-Computer Interface Elevated to 15th Five-Year Plan Industrial Strategy, Upstream and Downstream Collaboration to Build a New Human-Machine Integration Ecosystem

Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says

MT Newswires Live

Scholar Rock added to Best Ideas List at Wedbush

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/IBRN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":32.552,"timestamp":1790971200000,"preClose":32.8651,"halted":0,"volume":432,"hourTrading":{"tag":"盘后","latestPrice":32.545,"preClose":32.552,"latestTime":"17:07 EDT","volume":10,"amount":323.738,"timestamp":1790975268525,"change":-0.007,"changeRate":-0.000215,"amplitude":0},"delay":0,"changeRate":-0.00952682328670835,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"Market Closed","change":-0.3131,"latestTime":"10-02 16:00:00 EDT","open":32.561,"high":32.561,"low":32.545,"amount":14103,"amplitude":0.000487,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":32.8651,"sharesOutstanding":150000,"nav":32.771593,"aum":6554318.6,"dividendRate":0.00979,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":32.545,"preClose":32.552,"latestTime":"17:07 EDT","volume":10,"amount":323.738,"timestamp":1790975268525,"change":-0.007,"changeRate":-0.000215,"amplitude":0},"volumeRatio":0.308263,"impliedVol":0.0726,"impliedVolPercentile":0.3187},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.308263,"shares":200000,"dividePrice":0.3187,"high":32.561,"amplitude":0.000487,"preClose":32.8651,"low":32.545,"week52Low":27.16,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":32.552,"eps":0,"divideRate":0.00979,"volume":432,"delay":0,"ttmEps":0,"open":32.561,"prevYearClose":32.3193,"prevWeekClose":33.3342,"prevMonthClose":33.265,"prevQuarterClose":33.265,"fiveDayClose":33.3342,"twentyDayClose":39.3744,"sixtyDayClose":40.2891},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672974104","title":"Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $83,464.02","url":"https://stock-news.laohu8.com/highlight/detail?id=2672974104","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672974104?lang=en_us&edition=fundamental","pubTime":"2026-10-03 06:23","pubTimestamp":1790979782,"startTime":"0","endTime":"0","summary":"Alkermes EVP, CLO David Joseph Gaffin disposes of 2,034 common shares worth $83,464.02Alkermes EVP and chief legal officer David Joseph Gaffin sold 2,034 ordinary shares on Oct. 2, 2026.Sale price USD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL6fSlzc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $83,464.02","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","PSCH","FBT","BK4139","PSIL","ALKS","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672467557","title":"Xenon Grants 17,850 Inducement Stock Options, 10,500 RSUs to New Hires Under NASDAQ Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2672467557","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672467557?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:01","pubTimestamp":1790971282,"startTime":"0","endTime":"0","summary":"Xenon grants 17,850 inducement stock options, 10,500 RSUs to new hires under Nasdaq ruleXenon Pharmaceuticals issued inducement equity awards to eight new non-officer employees, totaling 17,850 share ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL4TdRtw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00BN0W2V16.EUR","BK4588","SG9999014021.USD","IE00BQXX3F31.USD","IE00B3QW5Z07.USD","BK4112","IE00BKPKM429.USD","LU2095319765.USD","IBRN","LU2210149790.SGD","LU2210150020.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","BK4139","BK4585","SG9999014039.USD","IE00BGHQF748.EUR","IE00BQXX3D17.EUR","IE00BQXX3C00.GBP","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","NDAQ","XENE","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672746732","title":"Praxis Precision Medicines Grants 3,478 Inducement RSUs to 14 New Employees Under 2024 Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2672746732","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672746732?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:01","pubTimestamp":1790971276,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines grants 3,478 inducement RSUs to 14 new employees under 2024 planPraxis Precision Medicines granted restricted stock units covering 3,478 common shares to 14 new non-executiv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL8n5PWp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","IE0009355771.USD","LU0889565916.HKD","PRAX","SG9999014013.SGD","IE00BJJMRZ35.SGD","IE0002141913.USD","BCDF","IE00BKPKM429.USD","NDAQ","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","SG9999014021.USD","BK4139","LU0109394709.USD","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","IE00B64PRP62.GBP","SG9999014039.USD","IE00BJT1NW94.SGD","IE00BQXX3C00.GBP","IE00BN0W2W23.USD","LU0320765992.SGD","BK4588","LU2210150020.SGD","IE00B2B36J28.USD","IE00BGHQF748.EUR","LU2210149790.SGD","IBRN","SG9999014005.SGD","BK4585","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672749997","title":"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672749997","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672749997?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:01","pubTimestamp":1790971260,"startTime":"0","endTime":"0","summary":"VANCOUVER, BC and BOSTON, MA, Oct.  02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical devel","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/02/3374010/33485/en/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE","IBRN","SBIO","LCLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672749918","title":"Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672749918","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672749918?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:01","pubTimestamp":1790971260,"startTime":"0","endTime":"0","summary":"Investor Contact:. 857-702-9452. Media Contact:. Dan Ferry. LifeSci Advisors. 617-430-7576","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/02/3374007/0/en/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","IE0002141913.USD","BK4200","BK4139","CNS","LU0109394709.USD","LU0320765992.SGD","IE00BFTCPJ56.SGD","ASO","LU0889565916.HKD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","IE0009355771.USD","BK4135","BK4561","IE00BJJMRZ35.SGD","PRAX","LCLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672379110","title":"Praxis Precision Medicines, Inc. : Jonestrading Raises Target Price to $534 from $441","url":"https://stock-news.laohu8.com/highlight/detail?id=2672379110","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672379110?lang=en_us&edition=fundamental","pubTime":"2026-10-02 12:50","pubTimestamp":1790916618,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nFWN45O04U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0009355771.USD","IE00BFTCPJ56.SGD","LU0320765992.SGD","IBRN","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","BK4139","LU0889565916.HKD","PRAX","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672235796","title":"Alkermes (ALKS), What Is Behind The Fresh Attention?","url":"https://stock-news.laohu8.com/highlight/detail?id=2672235796","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672235796?lang=en_us&edition=fundamental","pubTime":"2026-10-02 09:21","pubTimestamp":1790904114,"startTime":"0","endTime":"0","summary":"Alkermes (NasdaqGS:ALKS) is back on investors’ radar after releasing phase 1 proof of concept data for ALKS 7290 in adults with ADHD, showing clinically meaningful symptom improvements and supportive safety findings.\nRecent trading tells a mixed story for Alkermes. The share price is around $40.54, with a 30 day share price return down 14.11% and a 90 day move lower by 25.72%. Yet the year to date share price return is up 43.45% and the 1 year total shareholder return sits at 29.69%,...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/alkermes-alks-what-is-behind-the-fresh-attention","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/alkermes-alks-what-is-behind-the-fresh-attention","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MEDX","BK4139","PSIL","IBRN","ALKS","FBT","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672762734","title":"Dianthus Therapeutics Grants New Hires Stock Options for 106,000 Shares at $88.32 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2672762734","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672762734?lang=en_us&edition=fundamental","pubTime":"2026-10-02 05:00","pubTimestamp":1790888428,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics grants new hires stock options for 106,000 shares at $88.32 eachDianthus Therapeutics granted inducement equity awards on Oct. 1, 2026 to six newly hired non-executive employees.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL6JXktk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","LU2095319765.USD","BK4139","SG9999014039.USD","LU2210149790.SGD","IE00BQXX3D17.EUR","IE00BN0W2V16.EUR","IE00BQXX3F31.USD","BK4112","IE00B3QW5Z07.USD","BCDF","IE00B64PRP62.GBP","SG9999014021.USD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","NDAQ","DNTH","IE00BN0W2T93.GBP","BK4588","BK4585","LU0314104364.USD","SG9999014013.SGD","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014005.SGD","IE00BQXX3C00.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672762787","title":"Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672762787","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672762787?lang=en_us&edition=fundamental","pubTime":"2026-10-02 05:00","pubTimestamp":1790888400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUA955WXC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DNTH","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672991762","title":"Analyst Justin Walsh Reiterates Buy on Praxis as Upgraded Relutrigine Forecast Triples Long-Term Revenue Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2672991762","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672991762?lang=en_us&edition=fundamental","pubTime":"2026-10-02 04:35","pubTimestamp":1790886921,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Justin Walsh has reiterated their bullish stance on PRAX stock, giving a Buy rating on September 24. Justin Walsh has given hi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-justin-walsh-reiterates-buy-on-praxis-as-upgraded-relutrigine-forecast-triples-long-term-revenue-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-justin-walsh-reiterates-buy-on-praxis-as-upgraded-relutrigine-forecast-triples-long-term-revenue-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","IE0002141913.USD","IE00B2B36J28.USD","LU0320765992.SGD","IBRN","IE00BJT1NW94.SGD","PRAX","IE00B4R5TH58.HKD","BK4139","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672876399","title":"Xenon's AZK Approval Path Unlikely to Be Hurt by Safety Issues, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2672876399","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672876399?lang=en_us&edition=fundamental","pubTime":"2026-10-01 23:02","pubTimestamp":1790866926,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals'  safety data has raised investor concerns about a potential Food and Drug Administration warning for azetukalner, or AZK, though approval appears largely unaffected, RBC Capital Markets said Thursday in a report.Recent updates from the company's psychiatry program have raised investor concerns that neuropsychological adverse events may lead the FDA to add a warning, potentially even a boxed warning, to AZK's focal-onset seizures label, RBC said. Investors are also concerned that this could hurt AZK's commercial uptake and weigh on the stock, the report said.Based on historical precedent, AZK's data to date, and recent FDA feedback, RBC said it doesn't believe AZK is likely to receive a molecule-specific boxed warning, and that approval or commercial uptake isn't facing major risk.\"We continue to see $1.5 billion focal-onset seizures potential, justifying a higher valuation, and while acknowledging it may take time for investors to be reassured, view recent weakne","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SBIO","BK4139","XENE","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672813750","title":"Xenon Pharma CEO Ian Mortimer Acquires $1,121,400 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2672813750","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672813750?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:20","pubTimestamp":1790860804,"startTime":"0","endTime":"0","summary":"Xenon Pharma CEO Ian Mortimer acquires $1,121,400 in common sharesXenon Pharmaceuticals President and CEO Ian Mortimer bought 30,000 common shares at USD 37.38 each.Directly held stake rose to 49,923 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDLr2q46:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Xenon Pharma CEO Ian Mortimer Acquires $1,121,400 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRN","XENE","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157930495","title":"How to Build an OPC in Hebei","url":"https://stock-news.laohu8.com/highlight/detail?id=1157930495","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157930495?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:01","pubTimestamp":1790856101,"startTime":"0","endTime":"0","summary":"Entrepreneurship is becoming increasingly \"light.\" No need to gather partners, no need to build complex teams—one person or a few people, with the help of AI tools, can open a legitimate limited...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIX","VTHR","MNTL","QTOC","IBRN","CHAT","ARTY","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671521211","title":"Dianthus Therapeutics to Present Phase 3 Captivate Interim Analysis of Claseprubart in CIDP at 2026 AANEM Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2671521211","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671521211?lang=en_us&edition=fundamental","pubTime":"2026-09-29 20:01","pubTimestamp":1790683277,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics to present Phase 3 CAPTIVATE interim analysis of claseprubart in CIDP at 2026 AANEM meetingDianthus Therapeutics flagged new clinical updates for its complement inhibitor clasepr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL62W9hR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3F31.USD","IE00BKPKM429.USD","LU0314104364.USD","LU2210149790.SGD","LU2210150020.SGD","SG9999014039.USD","SG9999014005.SGD","BK4585","BK4588","IE00BN0W2V16.EUR","DNTH","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014021.USD","NDAQ","LU2095319765.USD","IBRN","IE00BN0W2W23.USD","BCDF","BK4139","IE00BQXX3D17.EUR","IE00BQXX3C00.GBP","BK4112","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671181299","title":"Defence Therapeutics Appoints Ex-Xenon CFO Sherry Aulin to Board, Audit Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2671181299","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671181299?lang=en_us&edition=fundamental","pubTime":"2026-09-29 15:16","pubTimestamp":1790666165,"startTime":"0","endTime":"0","summary":"Defence Therapeutics appoints ex-Xenon CFO Sherry Aulin to board, audit committeeDefence Therapeutics appointed finance executive Sherry Aulin to its board, adding her to the audit committee.Aulin was","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL177fM4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","BK4139","XENE","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186489707","title":"Sichuan to Leverage Technology So More People with Disabilities Can See, Hear, and Stand Up | Focus on \"15th Five-Year Plan\" Disability Support in Sichuan (Part 3)","url":"https://stock-news.laohu8.com/highlight/detail?id=1186489707","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186489707?lang=en_us&edition=fundamental","pubTime":"2026-09-28 16:01","pubTimestamp":1790582479,"startTime":"0","endTime":"0","summary":"In recent years, the advancement of cutting-edge technologies such as artificial intelligence and brain-computer interfaces has brought a glimmer of hope to more people with disabilities. During the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670283036","title":"Xenon Pharmaceuticals Inc. : Jefferies Cuts Target Price to $90 from $100","url":"https://stock-news.laohu8.com/highlight/detail?id=2670283036","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670283036?lang=en_us&edition=fundamental","pubTime":"2026-09-28 12:09","pubTimestamp":1790568563,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nFWN45I06J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","XENE","BK4139","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125295318","title":"China Securities Co., Ltd.: Brain-Computer Interface Elevated to 15th Five-Year Plan Industrial Strategy, Upstream and Downstream Collaboration to Build a New Human-Machine Integration Ecosystem","url":"https://stock-news.laohu8.com/highlight/detail?id=1125295318","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125295318?lang=en_us&edition=fundamental","pubTime":"2026-09-26 22:30","pubTimestamp":1790433022,"startTime":"0","endTime":"0","summary":"According to a research report released by China Securities Co., Ltd. (601066), the brain-computer interface has been elevated to a strategic direction for the 15th Five-Year Plan. With strong...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0276","MNTL","IBRN","601066"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670103426","title":"Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2670103426","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670103426?lang=en_us&edition=fundamental","pubTime":"2026-09-26 00:35","pubTimestamp":1790354150,"startTime":"0","endTime":"0","summary":"Scholar Rock (SRRK) is well positioned for a durable, de-risked commercial ramp in the neuromuscular space, driven by Isembyld's first-in-class launch in spinal muscular atrophy and a broadening myost","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IEFN","SRRK","IBRN","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670440123","title":"Scholar Rock added to Best Ideas List at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2670440123","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670440123?lang=en_us&edition=fundamental","pubTime":"2026-09-25 20:45","pubTimestamp":1790340341,"startTime":"0","endTime":"0","summary":"Wedbush is adding Outperform-rated Scholar Rock (SRRK) to the firm’s Best Ideas List. Wedbush believes the company is uniquely positioned to delive...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-added-to-best-ideas-list-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-added-to-best-ideas-list-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IBRN","THNR","SRRK"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}